NZ505294A - Use of fat-binding polymers in combination with one or more lipase inhibitors to treat obesity and hypertriglyceridemia and for reducing the absorption of dietary fat in mammals, and the use of fat-binding polymers to treat steatorrhea - Google Patents

Use of fat-binding polymers in combination with one or more lipase inhibitors to treat obesity and hypertriglyceridemia and for reducing the absorption of dietary fat in mammals, and the use of fat-binding polymers to treat steatorrhea

Info

Publication number
NZ505294A
NZ505294A NZ505294A NZ50529499A NZ505294A NZ 505294 A NZ505294 A NZ 505294A NZ 505294 A NZ505294 A NZ 505294A NZ 50529499 A NZ50529499 A NZ 50529499A NZ 505294 A NZ505294 A NZ 505294A
Authority
NZ
New Zealand
Prior art keywords
fat
binding polymers
treat
absorption
steatorrhea
Prior art date
Application number
NZ505294A
Other languages
English (en)
Inventor
W Mandeville
Original Assignee
Geltex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/166,453 external-priority patent/US6264937B1/en
Application filed by Geltex Pharma Inc filed Critical Geltex Pharma Inc
Publication of NZ505294A publication Critical patent/NZ505294A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Detergent Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
NZ505294A 1998-01-09 1999-01-04 Use of fat-binding polymers in combination with one or more lipase inhibitors to treat obesity and hypertriglyceridemia and for reducing the absorption of dietary fat in mammals, and the use of fat-binding polymers to treat steatorrhea NZ505294A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US496398A 1998-01-09 1998-01-09
US09/166,453 US6264937B1 (en) 1998-01-09 1998-10-05 Fat-binding polymers
PCT/US1999/000028 WO1999034787A2 (en) 1998-01-09 1999-01-04 Fat-binding polymers

Publications (1)

Publication Number Publication Date
NZ505294A true NZ505294A (en) 2003-02-28

Family

ID=26673719

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ505294A NZ505294A (en) 1998-01-09 1999-01-04 Use of fat-binding polymers in combination with one or more lipase inhibitors to treat obesity and hypertriglyceridemia and for reducing the absorption of dietary fat in mammals, and the use of fat-binding polymers to treat steatorrhea
NZ523301A NZ523301A (en) 1998-01-09 1999-01-04 A method for treating obesity by administering a fat-binding polymer that is substituted with a lipase inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ523301A NZ523301A (en) 1998-01-09 1999-01-04 A method for treating obesity by administering a fat-binding polymer that is substituted with a lipase inhibitor

Country Status (18)

Country Link
EP (1) EP1043981B1 (enExample)
JP (1) JP2002500183A (enExample)
KR (2) KR20060111741A (enExample)
CN (1) CN1212123C (enExample)
AT (1) ATE237349T1 (enExample)
AU (2) AU740233B2 (enExample)
BR (1) BR9907234A (enExample)
CA (1) CA2318417A1 (enExample)
DE (1) DE69906928T2 (enExample)
ES (1) ES2200493T3 (enExample)
HU (1) HUP0100890A3 (enExample)
IL (1) IL137096A (enExample)
MX (1) MX222446B (enExample)
NO (1) NO20003510L (enExample)
NZ (2) NZ505294A (enExample)
PL (1) PL193452B1 (enExample)
RU (1) RU2222335C2 (enExample)
WO (1) WO1999034787A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267952B1 (en) * 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
MXPA02000492A (es) * 1999-07-14 2002-07-02 Geltex Pharma Inc Polimeros enlazantes de grasas, opcionalmente combinados con inhibidores de lipasas.
EP1219297A4 (en) * 1999-10-01 2004-11-17 Amato Pharm Prod Ltd ACTIVE AGENTS AGAINST FATTY ADDICTION
KR100572785B1 (ko) 2000-07-28 2006-04-19 에프. 호프만-라 로슈 아게 신규한 약학 조성물
EP1379259A1 (en) 2001-04-18 2004-01-14 Genzyme Corporation Methods of treating syndrome x with aliphatic polyamines
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
SE0302253D0 (sv) * 2003-08-21 2003-08-21 Forskarpatent I Syd Ab Lipase-colipase inhibitor
CN106176800B (zh) * 2016-07-11 2019-12-06 韩源平 多聚阳离子树脂的制药应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7017227A (enExample) * 1969-12-27 1971-06-29
US4211765A (en) * 1971-10-12 1980-07-08 Monsanto Company Method for controlling obesity
US4432968A (en) * 1980-10-20 1984-02-21 The Dow Chemical Company Weight control with fat imbibing polymers
CA1213397A (en) * 1980-10-20 1986-10-28 Judith L. Page Weight control with alkyl styrene polymers
EP0354948A1 (fr) * 1988-02-12 1990-02-21 DE ZAEPFFEL, Brigitte Copolymere hydrophile reticule a usage medical et paramedical
RU2066185C1 (ru) * 1993-01-11 1996-09-10 Институт пищевых веществ РАН Гиполипидемический энтеросорбент
JP3507523B2 (ja) * 1993-05-12 2004-03-15 積水化学工業株式会社 糖質吸収抑制剤

Also Published As

Publication number Publication date
EP1043981A2 (en) 2000-10-18
HK1034044A1 (en) 2001-10-12
KR100773625B1 (ko) 2007-11-05
DE69906928D1 (de) 2003-05-22
AU1950599A (en) 1999-07-26
KR20010034013A (ko) 2001-04-25
MX222446B (en) 2004-09-01
ES2200493T3 (es) 2004-03-01
PL193452B1 (pl) 2007-02-28
MXPA00006681A (es) 2001-02-01
CN1288381A (zh) 2001-03-21
CN1212123C (zh) 2005-07-27
NO20003510L (no) 2000-09-07
KR20060111741A (ko) 2006-10-27
NO20003510D0 (no) 2000-07-07
AU2002014755A1 (en) 2002-03-14
HUP0100890A3 (en) 2001-12-28
IL137096A (en) 2006-10-31
HUP0100890A2 (hu) 2001-08-28
RU2222335C2 (ru) 2004-01-27
ATE237349T1 (en) 2003-05-15
CA2318417A1 (en) 1999-07-15
BR9907234A (pt) 2000-10-10
IL137096A0 (en) 2001-06-14
JP2002500183A (ja) 2002-01-08
PL343898A1 (en) 2001-09-10
DE69906928T2 (de) 2004-02-19
AU740233B2 (en) 2001-11-01
NZ523301A (en) 2005-11-25
EP1043981B1 (en) 2003-04-16
WO1999034787A3 (en) 2000-01-20
WO1999034787A2 (en) 1999-07-15

Similar Documents

Publication Publication Date Title
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
WO2002056895A3 (en) Ionene polymers and their use in treating mucositis
PL323825A1 (en) Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
PL338705A1 (en) Application of gaba analogues in preventing and treating gastrointestinal diseases
AU1718400A (en) Method for treating pain
PT880350E (pt) Tratamento de esclerose multipla
DE69715217D1 (de) Konjugierte linoleinsäure zur erhaltung oder erhöhung des knochenmineraliengehaltes
MXPA04002565A (es) Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
AU4726797A (en) Prophylactic/remedial agent
AU2196297A (en) Methods of treating or preventing interstitial cystitis
GB9903598D0 (en) Connective tissue healing
NO20003510D0 (no) Fett-bindende polymerer
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
IL130500A (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
IL118491A0 (en) Use of pyrrolidine derivatives in the treatment of alcoholism
ZA984433B (en) Use of low-molecular-weight heparins for the prevention and treatment of cerebral oedemas
WO2001095891A3 (en) Method for treating dehydration and a composition therefor
MY118982A (en) Method of reducing tissue damage associated with ischemia
BR9612549A (pt) Método para tratamento de agressão excessiva
GB9619631D0 (en) Combination therapy
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
IT1248026B (it) Composizione di trattamento di acque di rifiuto da destinare al riciclo,e procedimento di riciclo di acque di rifiuto che utilizza questa composizione.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: GENZYME CORPORATION, US

Free format text: OLD OWNER(S): GELTEX PHARMACEUTICALS, INC.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)